Electra Therapeutics — Third Quarter 2026 Earnings Summary

Financial Performance:

• Cash, cash equivalents, and marketable securities totaled $402.5 million as of September 30, 2026, including $320.0 million in net proceeds from the September 2026 IPO.
• Research and development expenses were $17.3 million for the third quarter of 2026, compared to $14.9 million in the same period of 2025.
• General and administrative expenses were $7.8 million for the third quarter of 2026, compared to $1.8 million in the same period of 2025.
• Net loss was $23.9 million for the third quarter of 2026, compared to a net loss of $18.1 million for the same period in 2025.
• For the nine months ended September 30, 2026, total operating expenses were $75.3 million compared to $42.4 million for the same period in 2025.
• Net loss for the nine months ended September 30, 2026, was $72.8 million, compared to $43.5 million for the same period in 2025.
• Net loss per share attributable to common stockholders was $(3.47) for the three months ended September 30, 2026, compared to $(616.86) for the same period in 2025.
• Working capital was $389.95 million as of September 30, 2026, compared to $85.76 million as of December 31, 2025.
• Total stockholders' equity was $392.9 million as of September 30, 2026, compared to a deficit of $163.4 million as of December 31, 2025.
• The company expects its current cash position to support planned operations into 2029.

Guidance and Future Outlook:

• Enrollment completion for the global registrational program (SURPASS) for ipsoprubart in sHLH is expected in the second half of 2027.
• Initial data from the Phase 1 trial for ipsoprubart in T/NK cell malignancies is expected in the second half of 2027.
• Healthy volunteer data for ELA822 is expected in the first half of 2027.
• The company plans to initiate a first-in-disease trial for ELA822 in patients with T cell-mediated immune disorders in mid-2027, subject to regulatory approval.
• Management anticipates several important milestones in 2027, including ELA822 healthy volunteer data followed by ipsoprubart data in T/NK cell malignancies and sHLH enrollment completion.

Business Segments and Product Lines:

• Ipsoprubart (ELA026): A novel pan-SIRP monoclonal antibody in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH).
  • In a Phase 1b trial involving 12 frontline patients with malignancy-associated HLH, ipsoprubart demonstrated 100% overall survival at eight weeks and a 100% overall response rate at the week four assessment.
  • The registrational program includes SURPASS (Phase 2/3 trial in newly diagnosed, treatment-naïve sHLH patients) and COMPASS (a retrospective natural history study for external control).
  • Ipsoprubart is also being evaluated as a single-agent therapy in patients with relapsed/refractory T/NK cell malignancies. Among eight sHLH patients with underlying T- or B-cell lymphomas, all eight had an objective tumor response and seven had complete responses.
• ELA822: A novel SIRPγ-specific antibody in development for chronic T cell-mediated immune and inflammatory diseases.
  • In nonclinical models of giant cell arteritis and graft-versus-host disease, ELA822 reduced cytotoxic T cell infiltration and inflammatory cytokine production, improving disease activity and survival.
  • A randomized, placebo-controlled Phase 1 trial in healthy volunteers was initiated in September 2026.
• ASH Abstracts: Two abstracts regarding sHLH healthcare claims data and preclinical SIRP expression data were accepted for presentation at the 2026 American Society of Hematology Annual Meeting.

Market and Competitive Landscape:

• Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for immune-mediated diseases and cancer.
• The company's approach targets signal regulatory proteins (SIRP) to selectively deplete disease-driving immune cells while preserving normal immune function.
• sHLH is described as a severe hyperinflammatory syndrome with no broadly approved therapies and consistently poor survival rates over the past two decades.
• The company claims a first-mover advantage in SIRP-targeted precision immune cell depletion.

Risks and Challenges:

• Uncertainty of clinical development and the risk that results from early or small trials may not predict later results.
• Potential delays in patient enrollment, particularly in rare diseases.
• Regulatory uncertainty regarding the acceptance of the registrational program design, including the external control study (COMPASS), to support approval.
• Reliance on third parties for manufacturing and clinical trials.
• Ability to protect intellectual property.
• History of losses and the need for additional capital.

Management Commentary and Tone:

• Kathy Dong, President and CEO, stated that the recent IPO positions the company to build on its first-mover advantage in SIRP-targeted precision immune cell depletion.
• Management highlighted deep expertise in SIRP biology and a proprietary library of SIRP-targeting antibodies as key enablers for therapeutic optionality across immune-mediated diseases and cancer.
• The tone is confident regarding the potential of ipsoprubart to address distinct pathogenic immune cell populations and create value for stakeholders.

Other Key Points:

• The company completed a $350 million IPO in September 2026 to fund the advancement of its SIRP-targeting portfolio.
• The IPO proceeds included $320.0 million in net proceeds after deducting underwriting discounts, commissions, and other offering expenses.
• The company has transitioned from a private entity with convertible preferred stock to a public company with common stock outstanding (6,889,670 shares for the quarter ended September 30, 2026).
• The company's lead product candidate, ipsoprubart, is also known as ELA026.
• The company plans to present data at the 2026 American Society of Hematology Annual Meeting on December 13, 2026.